Rare Diseases in Italy: Access to Care, Early Diagnosis & 6 Key Requests
The News in Brief
In recognition of , the Italian Society of Paediatrics (Sip) and Uniamo, the Italian Federation of Rare Diseases, have jointly issued an appeal highlighting critical gaps in access to care. Data released by the organizations indicate that approximately 70% of rare disease cases first present symptoms in infancy or early childhood, disproportionately affecting the pediatric population. However, fewer than 5% of these conditions currently have a specifically approved therapy.
The Clinical Complexity of Rare Diseases
Rare diseases, collectively, represent a significant public health challenge. While each individual condition affects a small percentage of the population, the sheer number of distinct rare diseases is substantial. In the pediatric field, these conditions frequently have a genetic basis and manifest with complex, multi-systemic symptoms, necessitating early diagnostic intervention to prevent long-term disability.
The management of rare diseases is often complicated by a limited understanding of their natural history. Initial symptoms can be nonspecific, mimicking common childhood ailments, leading to a “diagnostic delay.” This interval between symptom onset and definitive diagnosis – whether biochemical or genetic – can diminish the effectiveness of available therapeutic options.
Therapeutic Obstacles and Off-Label Drug Use
A central challenge in managing rare diseases is the scarcity of targeted therapies. Less than 5% of rare diseases have a specific, approved treatment. Often, innovative medications are initially developed and authorized for adult use, requiring pediatricians to adapt dosages and formulations for younger patients, a practice known as “off-label” use. This is often a clinical necessity when authorized alternatives for children are unavailable.
Using drugs outside their registered indications presents both bureaucratic and technical complexities. A child’s age and weight significantly influence how their body processes a drug – its pharmacokinetics and pharmacodynamics. Pediatric research is therefore crucial to establish evidence-based safety and efficacy, reducing therapeutic uncertainty.
Territorial Inequalities and Health Migration
Organizations report that accessing care for rare diseases is often hampered by bureaucratic and organizational obstacles. A significant issue is the availability of orphan drugs, which frequently lack specific pediatric indications. Significant territorial inequalities exist in access to innovative drugs, medical foods, assistive devices, and rehabilitation services across different Italian regions. This disparity often forces families to undertake “health migration,” traveling to specialized centers far from their homes.
The Importance of Proximity Medicine and Holistic Support
Modern medicine recognizes that treating a rare disease extends beyond administering medication. Nutritional support, neuromotor rehabilitation, and assistive technologies are essential components of improving prognosis and quality of life. However, fragmented services can create disparities in healthcare access, impacting clinical outcomes based on geographic location.
An effective care model requires close integration between specialized centers – where diagnosis and treatment plans are established – and the local healthcare network. This continuity of care allows for managing daily needs closer to home, reducing stress for patients and their families. Specific training for family pediatricians and the use of digital technologies are valuable tools for monitoring disease progression and preventing acute exacerbations.
Six Requests to Improve Assistance
Italian pediatricians have formalized six requests to institutions to improve care for patients with rare diseases:
- National Uniformity: Guarantee equitable access to therapies across all regions.
- Neonatal Screening: Strengthen and standardize newborn screening coverage, given the genetic origin of approximately 72% of rare diseases.
- Addressing the Pediatric Gap: Promote clinical trials for pediatric populations and streamline the use of off-label medications.
- Proximity Networks: Enhance collaboration between centers of excellence and family pediatricians, utilizing telemedicine.
- Holistic Support: Ensure comprehensive care, including nutrition, rehabilitation, and support for caregivers.
- Research: Invest in pediatric scientific research to drive healthcare advancements.
Early Diagnosis and Future Prospects
Neonatal screening is a powerful secondary prevention tool for identifying metabolic or genetic defects early in life. There is broad scientific consensus that identifying a condition before irreversible damage occurs can dramatically alter a patient’s life trajectory. Expanding and standardizing these tests nationwide is essential to ensure all newborns have an equal opportunity for timely intervention.
The future of rare disease management lies in increasingly personalized and multidisciplinary medicine. Beyond research into new molecules and gene therapies, refining holistic management models is crucial. Only through a comprehensive approach encompassing clinical, rehabilitative, and supportive care can we offer meaningful solutions for these conditions, which, despite their rarity, have a profound impact on the health of the pediatric population.
Rino Agostinani, president of Sip, emphasized the urgency of timely access to therapy, stating, “Every day of delay in accessing therapy is a piece of the future that we take away from these children.” Annalisa Scopinaro, president of Uniamo, highlighted the importance of early diagnosis and specialized training, announcing a memorandum of understanding with Sip for the distance learning course Knowing to assist 2.0. Scopinaro also underscored the need for pharmacological formulations tailored to children’s age and weight, avoiding dosage adjustments based on subjective interpretation.